RhumbLine Advisers
MRNS

RhumbLine Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

RhumbLine Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,709
Closed -$33.6K – 4410
2024
Q2 		$33.6K Sell
28,709
-48,389
-63% -$121K ﹤0.01% 3783
2024
Q1 		$697K Buy
77,098
+1,311
+2% +$12.7K ﹤0.01% 2455
2023
Q4 		$824K Buy
75,787
+5,082
+7% +$38.1K ﹤0.01% 2373
2023
Q3 		$569K Buy
70,705
+3,803
+6% +$31.6K ﹤0.01% 2543
2023
Q2 		$727K Buy
+66,902
New +$573K ﹤0.01% 2464
2022
Q2 		– Sell
-37,114
Closed -$347K – 3273
2022
Q1 		$347K Buy
37,114
+1,257
+4% +$12.5K ﹤0.01% 2591
2021
Q4 		$426K Sell
35,857
-925
-3% -$10.7K ﹤0.01% 2576
2021
Q3 		$419K Buy
36,782
+1,675
+5% +$23K ﹤0.01% 2623
2021
Q2 		$630K Buy
35,107
+9,131
+35% +$147K ﹤0.01% 2452
2021
Q1 		$402K Sell
25,976
-618
-2% -$8.94K ﹤0.01% 2587
2020
Q4 		$324K Buy
26,594
+3,797
+17% +$52.9K ﹤0.01% 2632
2020
Q3 		$293K Sell
22,797
-3,465
-13% -$29.9K ﹤0.01% 2528
2020
Q2 		$267K Buy
26,262
+7,831
+42% +$72K ﹤0.01% 2634
2020
Q1 		$150K Buy
18,431
+1,705
+10% +$14.8K ﹤0.01% 2678
2019
Q4 		$145K Buy
16,726
+626
+4% +$3.51K ﹤0.01% 2826
2019
Q3 		$99K Sell
16,100
-159
-1% -$1.28K ﹤0.01% 2887
2019
Q2 		$270K Buy
16,259
+2,320
+17% +$40.3K ﹤0.01% 2652
2019
Q1 		$233K Buy
13,939
+1,898
+16% +$27.3K ﹤0.01% 2679
2018
Q4 		$138K Buy
12,041
+3,954
+49% +$80K ﹤0.01% 2830
2018
Q3 		$323K Sell
8,087
-588
-7% -$16.7K ﹤0.01% 2478
2018
Q2 		$245K Buy
+8,675
New +$192K ﹤0.01% 2639

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

RhumbLine Advisers's MRNS Position: Q3 2024 in Review

RhumbLine Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 28,709 shares — an estimated $33.6K sold.

RhumbLine Advisers first reported a position in MRNS in Q2 2018 and held it in 21 quarters. The position peaked at $824K in Q4 2023. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • RhumbLine Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 28,709 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $33.6K.
  • RhumbLine Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 21 quarters.
  • RhumbLine Advisers's Marinus Pharmaceuticals, Inc position peaked at $824K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.